Home  /  Resource Library  /  The efficacy, safety, and rationale of orelabrutinib combined with obinutuzumab (O2) as a first-line systemic treatment for marginal zone lymphoma

The efficacy, safety, and rationale of orelabrutinib combined with obinutuzumab (O2) as a first-line systemic treatment for marginal zone lymphoma

Study investigated orelabrutinib combined with obinutuzumab for first line treatment of MZL.